Indexed in SCIE, Scopus, PubMed & PMC
pISSN 1226-4512 eISSN 2093-3827

Article

home Article View

Review Article

Korean J Physiol Pharmacol 2024; 28(2): 107-112

Published online March 1, 2024 https://doi.org/10.4196/kjpp.2024.28.2.107

Copyright © Korean J Physiol Pharmacol.

The role of 27-hydroxycholesterol in meta-inflammation

Yonghae Son1, Eunbeen Choi2, Yujin Hwang2, and Koanhoi Kim1,*

1Department of Pharmacology, 2Department of Medicine, School of Medicine, Pusan National University, Yangsan 50612, Korea

Correspondence to:Koanhoi Kim
E-mail: koanhoi@pusan.ac.kr

Author contributions: Y.S., E.C., Y.H., and K.K. drafted the manuscript. Y.S. and K.K. wrote and edited the manuscript.

Received: November 17, 2023; Revised: January 3, 2024; Accepted: January 9, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Go to

27-Hydroxycholesterol (27OHChol), a prominent cholesterol metabolite present in the bloodstream and peripheral tissues, is a kind of immune oxysterol that elicits immune response. Recent research indicates the involvement of 27OHChol in metabolic inflammation (meta-inflammation) characterized by chronic responses associated with metabolic irregularities. 27OHChol activates monocytic cells such that they secrete pro-inflammatory cytokines and chemokines, and increase the expression of cell surface molecules such as pattern-recognition receptors that play key roles in immune cell-cell communication and sensing metabolism-associated danger signals. Levels of 27OHChol increase when cholesterol metabolism is disrupted, and the resulting inflammatory responses can contribute to the development and complications of metabolic syndrome, including obesity, insulin resistance, and cardiovascular diseases. Since 27OHChol can induce chronic immune response by activating monocyte-macrophage lineage cells that play a crucial role in meta-inflammation, it is essential to understand the 27OHChol-induced inflammatory responses to unravel the roles and mechanisms of action of this cholesterol metabolite in chronic metabolic disorders.

Keywords: Atherosclerosis, Meta-inflammation, Monocytes/Macrophages, Obesity, 27-Hydroxycholesterol

INTRODUCTION

Go to

Cholesterol is a crucial component of cellular membranes, constituting approximately 20% of all membrane lipids. It plays a vital role in maintaining integrity and fluidity of cell membrane and cellular physiology [1]. However, cholesterol is susceptible to oxidation, resulting in the formation of oxysterols. Among oxysterols, 27-hydroxycholesterol (27OHChol), which is generated either by autooxidation or mitochondrial cytochrome P450 enzyme sterol 27-hydroxylase (CYP27A1), stands out as the most abundant oxysterol in the bloodstream and peripheral tissues [2-4]. It is a bioactive metabolite with remarkable implications for various biological processes, including cholesterol homeostasis, lipid metabolism, gene expression, and innate immune response [5-7].

27OHChol exerts pleiotropic effects on monocytic cells, inducing the differentiation and polarization of monocytes and macrophages into mature dendritic cell phenotype and pro-inflammatory M1 type, respectively [8,9]. Activated M1 monocytic cells display increased expression of cytokines, chemokines, and surface molecules related to inflammatory responses [7,10,11]. Given the association of M1 monocytic cell accumulation and oxysterol dysregulation with conditions such as atherosclerosis, adiposity and obesity [12-15], ongoing research seeks to explore the intricate mechanisms and implications of 27OHChol in human inflammatory diseases.

Metabolic inflammation, also known as meta-inflammation, is characterized by low-grade, chronic inflammation in metabolic disorders like cardiovascular diseases, obesity, and diabetes [16]. It differs substantially from acute inflammation regarding underlying causes, duration, and immune cell activation. While acute inflammation typically results from external factors like toxin exposure, microbial invasion or physical injury, meta-inflammation primarily stems from metabolic abnormalities [17]. Acute inflammation is transient, lasting for a short period, usually hours to days, while meta-inflammation persists for months or even years [18]. Meta-inflammation involves complex interactions among metabolic abnormalities, immune cells, and organs. It is featured by activation of monocytes/macrophages and release of pro-inflammatory cytokines in response to metabolic stress. These events lead to immune cell infiltration into affected tissues and dysregulated signaling pathways associated with development and progression of metabolic syndrome [16,18,19]. Therefore, understanding the unique characteristics of metabolic inflammation is pivotal for developing targeted approaches to manage and treat chronic metabolic disorders.

The objective of this review article is to highlight the involvement of 27OHChol in the pathophysiology of human diseases, particularly in the context of meta-inflammation. We presume that the activation of monocytic cells by 27OHChol can trigger and amplify inflammation, contributing to the progression and complications of major chronic diseases. By investigating the role of 27OHChol in meta-inflammation, we aim to gain insights into its part in the pathogenesis and treatment of chronic human diseases.

27OHCHOL AND CYTOKINES/CHEMOKINES

Go to

Cytokine and chemokine contribute to the establishment of chronic low-grade inflammation alongside with other inflammatory mediators [16,19]. 27OHChol enhances expression of both anti- and pro-inflammatory mediators in monocytic cells. However, it was noteworthy that the pro-inflammatory M1 molecules exhibit a significantly stronger expression, leading to an overall inflammatory response [8]. Studies from our laboratory have reported that cytokine and chemokines like CCL2, CCL3, CCL4, CXCL8, and tumor necrosis factor (TNF)-α are involved in 27OHChol-induced inflammatory responses.

27OHChol induces CCL2 secretion by liver X receptor-independent and Akt-dependent mechanisms, which indicates involvement of multiple pathways in CCL2 expression [20,21]. CCL2 binds to its receptor, C-C motif chemokine receptor-2 (CCR2), and recruits immune cells, particularly monocytes and macrophages, to sites of inflammation [22,23]. In agreement with the fact, CCL2 secreted from the 27OHChol-treated cells enhances monocytic cell migration through a CCR2-dependent mechanism [10,21]. Once recruited at the site of inflammation, monocytes differentiate into macrophages which are activated by pro-inflammatory molecules. These activated macrophages, in turn, release chemokines that attract more monocytes [24]. Unless the stimulus is removed, this vicious cycle of inflammatory response can persist for years, contributing to chronic low-grade inflammation. The monocyte- and macrophage-mediated response is central to the pathogenesis of obesity and atherosclerosis [18,24,25]. Therefore, the accumulation of 27OHChol in vasculature and adipose tissue can result in an increased number of monocytes and macrophages within the tissues via the CCL2/CCR2 axis, thereby promoting vascular and adipose tissue inflammation [12,15].

TNF-α is one of cytokines whose production is enhanced following exposure of monocytic cells to 27OHChol [26]. This cytokine influences adipose tissue inflammation, glucose metabolism, and cardiovascular remodeling through tissue-specific mechanisms [27]. TNF-α stimulates its own production within adipose tissue, creating a positive feedback loop that sustains inflammation, which perpetuates the pro-inflammatory environment in obesity [28]. TNF-α also directly impacts adipocyte function and metabolism since it impairs adipogenesis, resulting in adipocyte hypertrophy (enlarged fat cells) and adipose tissue dysfunction [28]. In addition, it interferes with adipocyte insulin signaling [29]. In the vasculature, TNF-α alters endothelial function, affecting the interaction between endothelial cells and blood cells and leading to vascular dysfunction [30], and increases the transcytosis of low-density lipoprotein (LDL) across endothelial cells, facilitating the accumulation of LDL in the subendothelial space of vessel walls and promoting early atherosclerosis [31]. Moreover, released TNF-α from tissues into the bloodstream can have systemic effects [27,32].

27OHCHol induces the expression of CXCL8/interleukin (IL)-8 in monocytic cells via CD88 [33]. CXCL8 plays a vital role in recruiting and activating neutrophils, immune cells involved in the early stages of host defense against infection and injury [34]. CXCL8 is implicated in the pathogenesis of atherosclerosis [35]. In the context of metabolic inflammation, upregulated CXCL8 expression has been observed in adipose tissue [36]. The increased expression of CXCL8 under conditions rich in 27OHChol may cause the recruitment and activation of immune cells that promote tissue damage.

27OHChol increases the production of CCL3 and CCL4 that preferentially enhance migration of T cells expressing the C-C chemokine receptor 5 (CCR5) [11]. CCR5, characteristic of Th1 T lymphocytes, is expressed at high levels on the surface of Th1 T cells [37]. In the process of 27OHChol-induced inflammatory response, Th1 cell movement increases towards the sites of inflammation, leading to Th1 dominant conditions. Th1 T cells induce further inflammation by secreting cytokines including interferon-gamma (IFN-γ) and TNF-α [38]. IFN-γ enhances activation of macrophages, aids foam cell formation, and causes destabilization of atherosclerotic plaques in the vasculature [39-41]. In adipose tissue, cytokines secreted from Th1 cells sustain local inflammatory responses by activating other immune cells, and therefore enhance adipose tissue inflammation and contribute to the development of metabolic diseases [42,43].

The role of Th1 T cells in type 2 diabetes is an area of active research. An imbalanced Th1/Th2 cytokine profile has been implicated in disease development and progression. Elevated Th1/Th2 cytokine ratios, such as IFN-γ/IL-5 and IL-2/IL-5, are correlated with type 2 diabetes and its complications, including retinopathy and cardiovascular issues [44]. This result suggests that an exaggerated Th1 response coupled with a relative decrease in the Th2 response may contribute to the pathogenesis of type 2 diabetes in a milieu rich in 27OHChol.

27OHCHOL AND PATTERN RECOGNITION RECEPTORS

Go to

27OHChol affects the expression of molecules on the cell surface in addition to secretion of cytokines and chemokines. Previous studies from our laboratory demonstrated that 27OHChol upregulates the levels of heat shock protein 60 and multiple CD molecules including CD80, CD83, CD88, CD105, CD137, and CD166 [9,45,46]. These increases in expression are important indicators because the individual molecules are involved in cell characteristics, differentiation, and function. 27OHChol also elevates levels of pattern recognition receptors (PRRs), like Toll-like receptor 6 (TLR6) and CD14 [10,47]. Considering the results of previous studies from our laboratory, 27OHChol seems to prime monocytic cells by upregulating the PRRs such that their metabolic ligands can trigger a cascade of signaling events enhancing inflammation.

27OHCHol upregulates TLR6 expression on cell surface, and the 27OHChol-activated monocytic cells secrete IL-1α in response to a TLR6 ligand [47]. Upon release, IL-1α binds to its receptor, leading to an innate immune response that activates PRRs due to IL-1α's similarity to infectious pathogens. Therefore, IL-1α promotes inflammation by inducing the production of other cytokines, chemokines, and small-molecule mediators [48]. This results in the systemic elevation of pro-inflammatory cytokines and transient reactions [49].

Monocytic cells activated with 27OHChol exhibit both increased expression of membrane-bound CD14 and enhanced secretion of soluble CD14 [20,45]. CD14 is crucial for the recognition of and response to lipopolysaccharide (LPS) [50]. The stimulation of monocytic cells with LPS in the presence of 27OHChol results in a super-induction of CCL2 compared with LPS alone [10], indicating that 27OHChol further enhances the CD14-mediated inflammatory pathway. However, the CD14 expression coupled with exaggerated LPS response and 27OHChol-induced inflammation were suppressed by treatment with anti-inflammatory drugs as well as HSP90 inhibitors [8,51-53]. CD14 also recognizes and binds various ligands associated with metabolic disorders. These ligands comprise oxidized LDL, a key contributor to atherosclerosis, and saturated fatty acids like palmitate and stearate that are elevated in obesity [54,55]. The CD14-mediated recognition of saturated fatty acids and other metabolic ligands promotes chronic low-grade inflammation and thereby can contribute to the pathogenesis and progression of insulin resistance, type 2 diabetes, and obesity [55-57]. Taken together, these findings suggest that 27OHChol is thought to be a key cholesterol metabolite involving CD14 in meta-inflammation.

CONCLUSION AND PROSPECTS

Go to

It has become evident that 27OHChol plays a key role in meta-inflammation, rendering it a pivotal factor in the development and progression of chronic diseases. This role is primarily attributed to its capacity to activate monocytes and macrophages and induce their expression of pro-inflammatory cytokines and chemokines, thereby disrupting metabolic signaling pathways (Fig. 1). Therefore, gaining a comprehensive understanding of the mechanisms and functions of 27OHChol in meta-inflammation is essential for the development of targeted approaches to manage and treat chronic metabolic disorders. We consider that the targeting of pathways involved in 27OHChol-induced inflammation may hold therapeutic promise for the new treatment of chronic metabolic disorders. In the absence of 27OHChol due to CYP27A1 deficiency, the human body manifests a disease known as Cerebrotendinous xanthomatosis, which is characterized by abnormal fat accumulation in the brain and joints [58]. Hence, excessive inhibition of sterol 27-hydroxylase to reduce 27OHChol levels is likely to result in secondary adverse effects. We suggest that it is imperative to develop drugs targeting the intermediate stages of 27OHChol-induced meta-inflammation to regulate chronic metabolic disorders.

Figure 1. The role of 27OHChol in metabolic syndrome. Dysfunction in cholesterol metabolism leads to increased accumulation of 27OHChol in tissues. The accumulated 27OHChol induces metabolic stress and low-grade inflammation by activating monocytic lineage cells. Unless 27OHChol is removed from affected tissues, the inflammatory response becomes chronic. The tissue-specific chronic inflammation induced by 27OHChol leads to metabolic syndrome. 27OHChol, 27-hydroxycholesterol.

References

Go to
  1. Cortes VA, Busso D, Maiz A, Arteaga A, Nervi F, Rigotti A. Physiological and pathological implications of cholesterol. Front Biosci (Landmark Ed). 2014;19:416-428.
    Pubmed CrossRef
  2. Brown AJ, Jessup W. Oxysterols and atherosclerosis. Atherosclerosis. 1999;142:1-28.
    Pubmed CrossRef
  3. Carpenter KL, Taylor SE, van der Veen C, Williamson BK, Ballantine JA, Mitchinson MJ. Lipids and oxidised lipids in human atherosclerotic lesions at different stages of development. Biochim Biophys Acta. 1995;1256:141-150.
    Pubmed CrossRef
  4. Garcia-Cruset S, Carpenter KL, Guardiola F, Stein BK, Mitchinson MJ. Oxysterol profiles of normal human arteries, fatty streaks and advanced lesions. Free Radic Res. 2001;35:31-41.
    Pubmed CrossRef
  5. Choi C, Finlay DK. Diverse immunoregulatory roles of oxysterols-the oxidized cholesterol metabolites. Metabolites. 2020;10:384.
    Pubmed KoreaMed CrossRef
  6. Schroepfer GJ Jr. Oxysterols: modulators of cholesterol metabolism and other processes. Physiol Rev. 2000;80:361-554.
    Pubmed CrossRef
  7. Umetani M, Shaul PW. 27-Hydroxycholesterol: the first identified endogenous SERM. Trends Endocrinol Metab. 2011;22:130-135.
    Pubmed KoreaMed CrossRef
  8. Lee J, Kim BY, Son Y, Giang DH, Lee D, Eo SK, Kim K. 4'OMethylalpinumisoflavone inhibits the activation of monocytes/macrophages to an immunostimulatory phenotype induced by 27hydroxycholesterol. Int J Mol Med. 2019;43:2177-2186.
    CrossRef
  9. Son Y, Kim SM, Lee SA, Eo SK, Kim K. Oxysterols induce transition of monocytic cells to phenotypically mature dendritic cell-like cells. Biochem Biophys Res Commun. 2013;438:161-168.
    Pubmed CrossRef
  10. Kim SM, Kim BY, Eo SK, Kim CD, Kim K. 27-Hydroxycholesterol up-regulates CD14 and predisposes monocytic cells to superproduction of CCL2 in response to lipopolysaccharide. Biochim Biophys Acta. 2015;1852:442-450.
    Pubmed CrossRef
  11. Kim SM, Kim BY, Lee SA, Eo SK, Yun Y, Kim CD, Kim K. 27-Hydroxycholesterol and 7alpha-hydroxycholesterol trigger a sequence of events leading to migration of CCR5-expressing Th1 lymphocytes. Toxicol Appl Pharmacol. 2014;274:462-470.
    Pubmed CrossRef
  12. Asghari A, Ishikawa T, Hiramitsu S, Lee WR, Umetani J, Bui L, Korach KS, Umetani M. 27-Hydroxycholesterol promotes adiposity and mimics adipogenic diet-induced inflammatory signaling. Endocrinology. 2019;160:2485-2494.
    Pubmed KoreaMed CrossRef
  13. Asghari A, Umetani M. Obesity and cancer: 27-hydroxycholesterol, the missing link. Int J Mol Sci. 2020;21:4822.
    Pubmed KoreaMed CrossRef
  14. Poli G, Biasi F, Leonarduzzi G. Oxysterols in the pathogenesis of major chronic diseases. Redox Biol. 2013;1:125-130.
    Pubmed KoreaMed CrossRef
  15. Umetani M, Ghosh P, Ishikawa T, Umetani J, Ahmed M, Mineo C, Shaul PW. The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha. Cell Metab. 2014;20:172-182.
    Pubmed KoreaMed CrossRef
  16. Ramos-Lopez O, Martinez-Urbistondo D, Vargas-Nuñez JA, Martinez JA. The role of nutrition on meta-inflammation: insights and potential targets in communicable and chronic disease management. Curr Obes Rep. 2022;11:305-335.
    Pubmed KoreaMed CrossRef
  17. Bonanni A, Vinci R, Pedicino D, Severino A, De Vita A, Filomia S, Brecciaroli M, Liuzzo G; d'Aiello A. Meta-inflammation and new anti-diabetic drugs: a new chance to knock down residual cardiovascular risk. Int J Mol Sci. 2023;24:8643.
    Pubmed KoreaMed CrossRef
  18. Qu L, Matz AJ, Karlinsey K, Cao Z, Vella AT, Zhou B. Macrophages at the crossroad of meta-inflammation and inflammaging. Genes (Basel). 2022;13:2074.
    Pubmed KoreaMed CrossRef
  19. Russo S, Kwiatkowski M, Govorukhina N, Bischoff R, Melgert BN. Meta-inflammation and metabolic reprogramming of macrophages in diabetes and obesity: the importance of metabolites. Front Immunol. 2021;12:746151.
    Pubmed KoreaMed CrossRef
  20. Kim BY, Son Y, Cho HR, Lee D, Eo SK, Kim K. 27-Hydroxycholesterol induces macrophage gene expression via LXR-dependent and -independent mechanisms. Korean J Physiol Pharmacol. 2021;25:111-118.
    Pubmed KoreaMed CrossRef
  21. Kim SM, Lee SA, Kim BY, Bae SS, Eo SK, Kim K. 27-Hydroxycholesterol induces recruitment of monocytic cells by enhancing CCL2 production. Biochem Biophys Res Commun. 2013;442:159-164.
    Pubmed CrossRef
  22. Chu HX, Arumugam TV, Gelderblom M, Magnus T, Drummond GR, Sobey CG. Role of CCR2 in inflammatory conditions of the central nervous system. J Cereb Blood Flow Metab. 2014;34:1425-1429.
    Pubmed KoreaMed CrossRef
  23. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011;11:762-774.
    Pubmed KoreaMed CrossRef
  24. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
    Pubmed CrossRef
  25. Gschwandtner M, Derler R, Midwood KS. More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis. Front Immunol. 2019;10:2759.
    Pubmed KoreaMed CrossRef
  26. Kim SM, Jang H, Son Y, Lee SA, Bae SS, Park YC, Eo SK, Kim K. 27-hydroxycholesterol induces production of tumor necrosis factor-alpha from macrophages. Biochem Biophys Res Commun. 2013;430:454-459.
    Pubmed CrossRef
  27. Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010;20:87-103.
    Pubmed KoreaMed CrossRef
  28. Cawthorn WP, Sethi JK. TNF-alpha and adipocyte biology. FEBS Lett. 2008;582:117-131.
    Pubmed KoreaMed CrossRef
  29. Nieto-Vazquez I, Fernández-Veledo S, Krämer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem. 2008;114:183-194. Erratum in: Arch Physiol Biochem. 2009;115:117.
    Pubmed CrossRef
  30. Kleinbongard P, Heusch G, Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther. 2010;127:295-314.
    Pubmed CrossRef
  31. Zhang Y, Yang X, Bian F, Wu P, Xing S, Xu G, Li W, Chi J, Ouyang C, Zheng T, Wu D, Zhang Y, Li Y, Jin S. TNF-α promotes early atherosclerosis by increasing transcytosis of LDL across endothelial cells: crosstalk between NF-κB and PPAR-γ. J Mol Cell Cardiol. 2014;72:85-94.
    Pubmed CrossRef
  32. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 2007;48:751-762.
    Pubmed CrossRef
  33. Kim SM, Lee CW, Kim BY, Jung YS, Eo SK, Park YC, Kim K. 27-Oxygenated cholesterol induces expression of CXCL8 in macrophages via NF-κB and CD88. Biochem Biophys Res Commun. 2015;463:1152-1158.
    Pubmed CrossRef
  34. Cambier S, Gouwy M, Proost P. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention. Cell Mol Immunol. 2023;20:217-251.
    Pubmed KoreaMed CrossRef
  35. Apostolakis S, Vogiatzi K, Amanatidou V, Spandidos DA. Interleukin 8 and cardiovascular disease. Cardiovasc Res. 2009;84:353-360.
    Pubmed CrossRef
  36. Silva BRD, Cirelli T, Nepomuceno R, Theodoro LH, Orrico SRP, Cirelli JA, Barros SP, Scarel-Caminaga RM. Functional haplotype in the interleukin8 (CXCL8) gene is associated with type 2 diabetes mellitus and periodontitis in Brazilian population. Diabetes Metab Syndr. 2020;14:1665-1672.
    Pubmed CrossRef
  37. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, Dayer JM. CCR5 is characteristic of Th1 lymphocytes. Nature. 1998;391:344-345.
    Pubmed CrossRef
  38. Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis. 1999;5:285-294.
    Pubmed CrossRef
  39. Chen J, Xiang X, Nie L, Guo X, Zhang F, Wen C, Xia Y, Mao L. The emerging role of Th1 cells in atherosclerosis and its implications for therapy. Front Immunol. 2023;13:1079668.
    Pubmed KoreaMed CrossRef
  40. Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. Nat Rev Cardiol. 2020;17:387-401.
    Pubmed KoreaMed CrossRef
  41. Taleb S. Inflammation in atherosclerosis. Arch Cardiovasc Dis. 2016;109:708-715.
    Pubmed CrossRef
  42. Van Herck MA, Weyler J, Kwanten WJ, Dirinck EL, De Winter BY, Francque SM, Vonghia L. The differential roles of T cells in non-alcoholic fatty liver disease and obesity. Front Immunol. 2019;10:82.
    Pubmed KoreaMed CrossRef
  43. Wang Q, Wang Y, Xu D. The roles of T cells in obese adipose tissue inflammation. Adipocyte. 2021;10:435-445.
    Pubmed KoreaMed CrossRef
  44. Mahlangu T, Dludla PV, Nyambuya TM, Mxinwa V, Mazibuko-Mbeje SE, Cirilli I, Marcheggiani F, Tiano L, Louw J, Nkambule BB. A systematic review on the functional role of Th1/Th2 cytokines in type 2 diabetes and related metabolic complications. . Cytokine. 2020;126:154892.
    Pubmed CrossRef
  45. Kim BY, Son Y, Choi J, Eo SK, Park YC, Kim K. 27-Hydroxycholesterol upregulates the production of heat shock protein 60 of monocytic cells. J Steroid Biochem Mol Biol. 2017;172:29-35.
    Pubmed CrossRef
  46. Son Y, Kim BY, Park YC, Eo SK, Cho HR, Kim K. PI3K and ERK signaling pathways are involved in differentiation of monocytic cells induced by 27-hydroxycholesterol. Korean J Physiol Pharmacol. 2017;21:301-308.
    Pubmed KoreaMed CrossRef
  47. Heo W, Kim SM, Eo SK, Rhim BY, Kim K. FSL-1, a Toll-like receptor 2/6 agonist, induces expression of interleukin-1α in the presence of 27-hydroxycholesterol. Korean J Physiol Pharmacol. 2014;18:475-480.
    Pubmed KoreaMed CrossRef
  48. Malik A, Kanneganti TD. Function and regulation of IL-1α in inflammatory diseases and cancer. Immunol Rev. 2018;281:124-137.
    Pubmed KoreaMed CrossRef
  49. Tahtinen S, Tong AJ, Himmels P, Oh J, Paler-Martinez A, Kim L, Wichner S, Oei Y, McCarron MJ, Freund EC, Amir ZA, de la Cruz CC, Haley B, Blanchette C, Schartner JM, Ye W, Yadav M, Sahin U, Delamarre L, Mellman I. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol. 2022;23:532-542.
    Pubmed CrossRef
  50. Baumann CL, Aspalter IM, Sharif O, Pichlmair A, Blüml S, Grebien F, Bruckner M, Pasierbek P, Aumayr K, Planyavsky M, Bennett KL, Colinge J, Knapp S, Superti-Furga G. CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med. 2010;207:2689-2701.
    Pubmed KoreaMed CrossRef
  51. Choi J, Kim BY, Son Y, Lee D, Hong YS, Kim MS, Kim K. Reblastatins inhibit phenotypic changes of monocytes/macrophages in a milieu rich in 27-hydroxycholesterol. Immune Netw. 2020;20:e17.
    Pubmed KoreaMed CrossRef
  52. Kim BY, Son Y, Kim MS, Kim K. Prednisolone suppresses the immunostimulatory effects of 27-hydroxycholesterol. Exp Ther Med. 2020;19:2335-2342.
    Pubmed KoreaMed CrossRef
  53. Kim BY, Son Y, Lee J, Choi J, Kim CD, Bae SS, Eo SK, Kim K. Dexamethasone inhibits activation of monocytes/macrophages in a milieu rich in 27-oxygenated cholesterol. PLoS One. 2017;12:e0189643.
    Pubmed KoreaMed CrossRef
  54. Kang YE, Joung KH, Kim JM, Lee JH, Kim HJ, Ku BJ. Serum CD14 concentration is associated with obesity and insulin resistance in non-diabetic individuals. J Int Med Res. 2022;50:3000605221130010.
    Pubmed KoreaMed CrossRef
  55. Leite F, Leite Â, Santos A, Lima M, Barbosa J, Cosentino M, Ribeiro L. Predictors of subclinical inflammatory obesity: plasma levels of leptin, very low-density lipoprotein cholesterol and CD14 expression of CD16+ monocytes. Obes Facts. 2017;10:308-322.
    Pubmed KoreaMed CrossRef
  56. Duan J, Liu H, Chen J, Li X, Li P, Zhang R. Changes in gene expression of adipose tissue CD14+ cells in patients with Type 2 diabetes mellitus and their relationship with environmental factors. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021;46:1-10.
  57. Wu Z, Zhang Z, Lei Z, Lei P. CD14: biology and role in the pathogenesis of disease. Cytokine Growth Factor Rev. 2019;48:24-31.
    Pubmed CrossRef
  58. Björkhem I, Leitersdorf E. Sterol 27-hydroxylase deficiency: a rare cause of xanthomas in normocholesterolemic humans. Trends Endocrinol Metab. 2000;11:180-183.
    Pubmed CrossRef

Stats or Metrics

Share this article on :

Related articles in KJPP

more

ⓒ 2019. The Korean Journal of Physiology & Pharmacology. Powered by INFOrang Co., Ltd